NPM1 and acute myeloid leukemia: Arming NK cells with neoepitope-specific CARs remarkably improve their anti-tumor responses to NPM1-mutated AML without causing off-target toxicity.432 Moreover, NK cells further prime the DC maturation and neoantigen presentation via releasing GM-CSF, and recruit neoantigen-specific CCR5+CD8+ T cells by producing CCL5.433 Thus, the variety of cancer types amenable to immunotherapy increases as a result of modified NK cells.7